Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection
- Author(s)
- Adair, A; Tan, LL; Feng, J; Girkin, J; Bryant, N; Wang, M; Mordant, F; Chan, LJ; Bartlett, NW; Subbarao, K; Pymm, P; Tham, WH;
- Journal Title
- Journal of Virology
- Publication Type
- May 6 epub ahead of print
- Abstract
- Human coronavirus (hCoV) OC43 is endemic to global populations and usually causes asymptomatic or mild upper respiratory tract illness. Here, we demonstrate the neutralization efficacy of isolated nanobodies from alpacas immunized with the S1(B) and S1(C) domain of the hCoV-OC43 spike glycoprotein. A total of 40 nanobodies bound to recombinant OC43 protein with affinities ranging from 1 to 149 nM. Two nanobodies WNb 293 and WNb 294 neutralized virus at 0.21 and 1.79 nM, respectively. Intranasal and intraperitoneal delivery of WNb 293 fused to an Fc domain significantly reduced nasal viral load in a mouse model of hCoV-OC43 infection. Using X-ray crystallography, we observed that WNb 293 bound to an epitope on the OC43 S1B domain, distal from the sialoglycan-binding site involved in host cell entry. This result suggests that neutralization mechanism of this nanobody does not involve disruption of glycan binding. Our work provides characterization of nanobodies against hCoV-OC43 that blocks virus entry and reduces viral loads in vivo and may contribute to future nanobody-based therapies for hCoV-OC43 infections. IMPORTANCE: The pandemic potential presented by coronaviruses has been demonstrated by the ongoing COVID-19 pandemic and previous epidemics caused by severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus. Outside of these major pathogenic coronaviruses, there are four endemic coronaviruses that infect humans: hCoV-OC43, hCoV-229E, hCoV-HKU1, and hCoV-NL63. We identified a collection of nanobodies against human coronavirus OC43 (hCoV-OC43) and found that two high-affinity nanobodies potently neutralized hCoV-OC43 at low nanomolar concentrations. Prophylactic administration of one neutralizing nanobody reduced viral loads in mice infected with hCoV-OC43, showing the potential for nanobody-based therapies for hCoV-OC43 infections.
- Publisher
- ASM
- Keywords
- X-ray crystallography; anti-viral therapeutics; coronavirus; nanobodies
- Research Division(s)
- Infectious Diseases And Immune Defence
- PubMed ID
- 38709106
- Publisher's Version
- https://doi.org/10.1128/jvi.00531-24
- Open Access at Publisher's Site
https://doi.org/10.1128/jvi.00531-24.- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-05-08 10:06:29
Last Modified: 2024-05-08 10:15:57